Exelixis rises after cancer therapy succeeds in late-stage study

Shares of drugmaker Exelixis EXEL.O rise 23.8% to $49.97 premarket

EXEL on Sunday said its experimental oral therapy zanzalintinib, combined with Roche's ROG.S Tecentriq, improved survival in patients with a type of colorectal cancer in a late-stage study

Colorectal cancer develops in the colon’s inner lining and is the third most common cancer, according to CDC

Males are more likely to develop this type of cancer than females

As of last close, EXEL stock up 21.23% YTD